Cardiac implantable electronic devices with a defibrillator component and all‐cause mortality in left ventricular assist device carriers: results from the PCHF‐VAD registry

Cikes, Maja;Jakus, Nina;Claggett, Brian;Brugts, Jasper J.;Ruschitzka, Frank;et.al.
(2019) European Journal of Heart Failure — Vol. 21, n° 9, p. 1129-1141 (2019)

Files

2019_EJHF_PCHF-VAD_Cikes_et_al.pdf
  • Open Access
  • Adobe PDF
  • 295.72 KB
Download

Details

Authors
  • Cikes, Maja
    Author
  • Jakus, Nina
    Author
  • Claggett, Brian
    Author
  • Brugts, Jasper J.
    Author
  • Pouleur, Anne-CatherineUCLouvain
    Author
  • Jacquet, Luc-MarieUCLouvain
    Author
  • Houard, LauraUCLouvain
    Author
  • Ruschitzka, Frank
    Author
Show more
Abstract
(en) AIMS: To compare characteristics of left ventricular assist device (LVAD) recipients receiving a cardiac implantable electronic device (CIED) with a defibrillator component (implantable cardioverter-defibrillator and cardiac resynchronization therapy with defibrillation, CIED-D) vs. those without one, and to assess whether carrying such a device contiguously with an LVAD is associated with outcomes. METHODS AND RESULTS: Overall, 448 patients were analysed (mean age 52 ± 13 years, 82% male) in the multicentre European PCHF-VAD registry. To account for all active CIED-Ds during ongoing LVAD treatment, outcome analyses were performed by a time-varying analysis with active CIED-D status post-LVAD as the time-varying covariate. At the time of LVAD implantation, 235 patients (52%) had an active CIED-D. Median time on LVAD support was 1.1 years (interquartile range 0.5-2.0 years). A reduction of 36% in the risk of all-cause mortality was observed in patients with an active CIED-D [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.46-0.91; P = 0.012), increasing to 41% after adjustment for baseline covariates (HR 0.59, 95% CI 0.40-0.87; P = 0.008) and 39% after propensity score adjustment (HR 0.61, 95% CI 0.39-0.94; P = 0.027). Other than CIED-D, age, LVAD implant as redo surgery, number of ventricular arrhythmia episodes and use of vasopressors pre-LVAD were remaining significant risk factors of all-cause mortality. Incident ventricular arrhythmias post-LVAD portended a 2.4-fold and 2.6-fold increased risk of all-cause and cardiovascular death, respectively; carrying an active CIED-D remained associated with a 47% and 43% reduction in these events, respectively. CONCLUSIONS: In an analysis accounting for all active CIED-Ds, including those implanted during LVAD support, carrying such a device was associated with significantly better survival during LVAD support.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Cikes, M., Jakus, N., Claggett, B., Brugts, J. J., Timmermans, P., Pouleur, A.-C., Rubis, P., Van Craenenbroeck, E. M., Gaizauskas, E., Grundmann, S., Paolillo, S., Barge‐Caballero, E., D’Amario, D., Gkouziouta, A., Planinc, I., Veenis, J. F., Jacquet, L.-M., Houard, L., Holcman, K., et al. (2019). Cardiac implantable electronic devices with a defibrillator component and all‐cause mortality in left ventricular assist device carriers: results from the PCHF‐VAD registry. European Journal of Heart Failure, 21(9), 1129-1141. https://doi.org/10.1002/ejhf.1568 (Original work published 2019)